Medical aesthetic device company Candela has signed an exclusive collaboration agreement to commercialise MT.DERM’s medical microneedling products globally.
As agreed, Candela will commercialise MT.DERM’s Exceed medical microneedling system used to treat facial wrinkles and facial acne scars.
The dual-indicated, FDA-cleared Exceed system will be first launched in the US, followed by distribution in other countries. The system has also secured CE marking in Europe.
Candela CEO Geoffrey Crouse said: “We are delighted to enter into a partnership with MT.DERM, based on their superior engineering and deep understanding of needling technology.
“Microneedling is an essential component of any medical aesthetics practice. The addition of the Exceed medical microneedling system strengthens Candela’s product portfolio, which continues to provide customers the most comprehensive offering of best-in-class medical aesthetic technologies.”
Candela existing microneedling portfolio includes Profound system, which is a real-time, temperature-controlled, long pulse radiofrequency (RF) microneedling device.
MT.DERM founder and CEO Joern Kluge said: “Candela and MT.DERM jointly have the industry experience and reputation to make the Exceed device a leader in the mechanical microneedling global market.”
The agreement between Candela and MT.DERM also includes the option to add new products for commercialisation in the future.
Candela operates as a global medical aesthetic device company marketing its products to 86 countries.
It specialises in offering solutions for medical aesthetic applications for traumatic and surgical scar treatments, women’s health treatments, wrinkle reduction and tattoo removal, among others.
Apex Partners acquired the company in July 2017.